1 Study Coverage
1.1 Prostate Cancer Nuclear Medicine Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022) & (US$ Million) Introduction
1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Outlook 2017 VS 2022 VS 2028
1.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size for the Year 2017-2028
1.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size for the Year 2017-2028
1.3 Prostate Cancer Nuclear Medicine Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Prostate Cancer Nuclear Medicine Diagnostics in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Prostate Cancer Nuclear Medicine Diagnostics Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Prostate Cancer Nuclear Medicine Diagnostics Market Dynamics
1.4.1 Prostate Cancer Nuclear Medicine Diagnostics Industry Trends
1.4.2 Prostate Cancer Nuclear Medicine Diagnostics Market Drivers
1.4.3 Prostate Cancer Nuclear Medicine Diagnostics Market Challenges
1.4.4 Prostate Cancer Nuclear Medicine Diagnostics Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Prostate Cancer Nuclear Medicine Diagnostics by Type
2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Segment by Type
2.1.1 SPECT
2.1.2 PET
2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2017, 2022 & 2028)
2.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2017-2028)
2.4 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2017, 2022 & 2028)
2.5 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2017-2028)
3 Prostate Cancer Nuclear Medicine Diagnostics by Application
3.1 Prostate Cancer Nuclear Medicine Diagnostics Market Segment by Application
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2017, 2022 & 2028)
3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2017-2028)
3.4 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2017, 2022 & 2028)
3.5 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2017-2028)
4 Global Prostate Cancer Nuclear Medicine Diagnostics Competitor Landscape by Company
4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Company
4.1.1 Top Global Prostate Cancer Nuclear Medicine Diagnostics Companies Ranked by Revenue (2021)
4.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue by Player (2017-2022)
4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Concentration Ratio (CR)
4.2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Prostate Cancer Nuclear Medicine Diagnostics in 2021
4.2.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Prostate Cancer Nuclear Medicine Diagnostics Headquarters, Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Headquarters and Area Served
4.3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Companies Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Prostate Cancer Nuclear Medicine Diagnostics Market Size by Company
4.5.1 Top Prostate Cancer Nuclear Medicine Diagnostics Players in United States, Ranked by Revenue (2021)
4.5.2 United States Prostate Cancer Nuclear Medicine Diagnostics Revenue by Players (2020, 2021 & 2022)
5 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region
5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2017-2028)
5.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region: 2017-2022
5.2.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth 2017-2028
6.1.2 North America Prostate Cancer Nuclear Medicine Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth 2017-2028
6.3.2 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth 2017-2028
6.4.2 Latin America Prostate Cancer Nuclear Medicine Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Prostate Cancer Nuclear Medicine Diagnostics Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Blue Earth Diagnostics
7.1.1 Blue Earth Diagnostics Company Details
7.1.2 Blue Earth Diagnostics Business Overview
7.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.1.5 Blue Earth Diagnostics Recent Development
7.2 PETNET Solutions
7.2.1 PETNET Solutions Company Details
7.2.2 PETNET Solutions Business Overview
7.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.2.5 PETNET Solutions Recent Development
7.3 Cardinal Health
7.3.1 Cardinal Health Company Details
7.3.2 Cardinal Health Business Overview
7.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.3.5 Cardinal Health Recent Development
7.4 Lantheus Medical Imaging
7.4.1 Lantheus Medical Imaging Company Details
7.4.2 Lantheus Medical Imaging Business Overview
7.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.4.5 Lantheus Medical Imaging Recent Development
7.5 Jubilant Pharma
7.5.1 Jubilant Pharma Company Details
7.5.2 Jubilant Pharma Business Overview
7.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.5.5 Jubilant Pharma Recent Development
7.6 NCM-USA
7.6.1 NCM-USA Company Details
7.6.2 NCM-USA Business Overview
7.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.6.5 NCM-USA Recent Development
7.7 Progenics Pharma
7.7.1 Progenics Pharma Company Details
7.7.2 Progenics Pharma Business Overview
7.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.7.5 Progenics Pharma Recent Development
7.8 Telix Pharma
7.8.1 Telix Pharma Company Details
7.8.2 Telix Pharma Business Overview
7.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.8.5 Telix Pharma Recent Development
7.9 ImaginAb
7.9.1 ImaginAb Company Details
7.9.2 ImaginAb Business Overview
7.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.9.5 ImaginAb Recent Development
7.10 Theragnostics
7.10.1 Theragnostics Company Details
7.10.2 Theragnostics Business Overview
7.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.10.5 Theragnostics Recent Development
7.11 Novartis
7.11.1 Novartis Company Details
7.11.2 Novartis Business Overview
7.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.11.5 Novartis Recent Development
7.12 Alliance Medical
7.12.1 Alliance Medical Company Details
7.12.2 Alliance Medical Business Overview
7.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
7.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2017-2022)
7.12.5 Alliance Medical Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
